While many investors like to look for momentum in stocks, this can be very tough to define. There is a lot of debate surrounding which metrics are the best to focus on and which are poor quality indicators of future performance. The Zacks Momentum Style Score, part of the Zacks Style Scores, helps address this issue for us. It's also important to note that Style Scores work as a complement to the Zacks Rank, our stock rating system that has an impressive track record of outperformance. Sarepta Therapeutics ...

Sarepta developed Elevidys in collaboration with Roche (RHHBY) . Both companies entered into a licensing agreement in 2019 to develop and market Elevidys. Per the agreement, Sarepta is responsible for marketing the therapy in the United States, while Roche is responsible for marketing the gene therapy outside the country. Sarepta is also eligible to receive collaboration revenues on the ex-U.S. sales made by Roche. This latest approval significantly expands the company's target market as it can increase its ...

Sarepta Therapeutics (SRPT) shares ended the last trading session 30.1% higher at $160.72. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 2.9% loss over the past four weeks. The label expansion is mainly supported by data from the phase III EMBARK study, announced last October. Though the study failed to achieve its primary endpoint, it achieved statistical significance on all pre-specified key secondary endpoints ...

Shares of Sarepta (SRPT) rose nearly 34% in after-market trading on Thursday after it announced that the FDA approved the expanded use of its Duchenne muscular dystrophy (DMD) gene therapy Elevidys. Elevidys is now approved to treat all DMD patients aged four years and older. While the FDA granted traditional approval for the therapy to treat ambulatory DMD patients (those who can still walk), it has granted accelerated approval for non-ambulatory patients. The label expansion is mainly supported by data fr ...

Sarepta Therapeutics $167.85 +44.35 (+35.91%) 52-Week Range $55.25 $173.25 P/E Ratio 1,525.91 Price Target $164.00 Add to Watchlist Sarepta Therapeutics NASDAQ: SRPT is leading the game in precision genetic medicine and biotechnology. Sarepta Therapeutics' stock price has witnessed a surge of over 40% after receiving expanded FDA approval for its Duchenne muscular dystrophy (DMD) gene therapy, Elevidys. This pivotal decision marks a turning point in treating this debilitating disease and underscores Sarepta ...

About Emily Jarvie Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced independently by our experienced and qualified teams of news journalists. The team delivers news and unique insights across the market including but not confined to: biotech and pharma, mining and natural resources, battery metals, oil and gas, crypto and emerging digital and EV technologies. ...

SRPT stock, which traded below $117 per share early on June 20, was trading at nearly $160 in pre-market trading this morning. This brought the market capitalization from $11.7 billion to nearly $16 billion. Elevidys, Sarepta's gene therapy, is a single-dose infusion usually given to children in the early stages of the disease. The agency gave traditional approval for these patients and accelerated approval for older ones. Sarepta CEO Doug Ingram called approval "a defining moment for the Duchenne community ...

Loading... Confirming the functional benefits, the FDA granted traditional approval for ambulatory patients (patients who can walk) and accelerated approval for non-ambulatory patients (patients who cannot walk). Continued approval for non-ambulatory Duchenne patients may be contingent upon verification of clinical benefit in a confirmatory trial. ELEVIDYS is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the DMD gene. Consistent with the accelerated approval pathway, Sarepta will ...

Kagenmi/iStock via Getty Images Sarepta Therapeutics, Inc. (NASDAQ:SRPT), submitted a request to the FDA aiming to erase the ambulation and age restrictions for Elevidys, as well as a switch in the designation from accelerated to standard approval. The company reported, in its Q1 2024 conference call, that the FDA will be issuing a response by June 21st or earlier. SRPT's management seems very certain about their chances to obtain the label expansion. However, I believe the FDA has enough grounds to support ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Q1 2024 Earnings Conference Call May 1, 2024 4:30 PM ET Company Participants Mary Jenkins - Associate Director, Investor Relations & Corporate Communications Douglas Ingram - President & Chief Executive Officer Dallan Murray - Executive Vice President & Chief Customer Officer Louise Rodino-Klapac - Executive Vice President, Chief Scientific Officer & Head of Research & Development Ian Estepan - Executive Vice President and Chief Financial Officer Conference Call Part ...